Chewy Revenue Breakdown & Fiscal Growth

Chewy's financial trajectory from its founding through its current public market life is a study in the tension between growth investment and path to profitability — a narrative that ultimately resolved in favor of the bulls when the company posted its first full-year GAAP profit in fiscal 2024. The company scaled from approximately $2 billion in net sales in fiscal 2017 (the year PetSmart acquired it) to $11.15 billion in fiscal 2024, compounding at a rate that consistently outpaced the broader pet industry and the e-commerce sector. This growth was not accidental — it was the product of systematic investment in fulfillment infrastructure, customer acquisition, product catalog expansion, and technology development. The cost of this investment was sustained operating losses that stretched from the company's founding through fiscal 2023. Chewy's gross margin profile is structurally constrained by its product mix. Pet food, which constitutes the majority of revenue, is a high-weight, low-margin category where shipping costs represent a significant percentage of product value. A 40-pound bag of premium dog food might retail for $65 — but shipping it from a fulfillment center in Pennsylvania to a customer in Arizona costs $8–12, compressing the unit economics meaningfully. Chewy has addressed this through several mechanisms: the scale-driven reduction in per-unit shipping rates through carrier negotiations, the geographic expansion of fulfillment centers to reduce average shipping distances, and the deliberate growth of higher-margin categories like pharmacy and health products. Gross margins expanded from approximately 25% in fiscal 2019 to approximately 29.5% in fiscal 2024, reflecting these structural improvements. The shift in revenue mix toward Chewy Health products — where pharmacy gross margins can approach 40–50% — is the most impactful driver of this expansion and represents the largest financial opportunity in Chewy's medium-term roadmap. Selling, general, and administrative expenses (SG&A) as a percentage of net sales declined meaningfully as the company scaled, dropping from over 30% in earlier years to approximately 27% in fiscal 2024. Customer service costs, which are unusually high at Chewy relative to competitors due to the company's service philosophy, represent a significant component of SG&A — but also a strategic investment in retention. The lifetime value of a customer who has had a memorable service interaction justifies costs that would appear excessive in a pure operational efficiency framework. Technology and development expenditure has been sustained and growing, reflecting Chewy's investment in its health platform infrastructure, personalization capabilities, pharmacy fulfillment systems, and veterinary software products. These investments carry long payback periods but build compounding competitive assets that are difficult for competitors to replicate quickly. Free cash flow generation became positive in fiscal 2023 and has strengthened since, providing Chewy with the financial flexibility to fund health platform investments, potential acquisitions, and shareholder returns without relying on external capital markets. This transition is strategically significant because it removes the execution risk of running an extended cash-burn model and demonstrates that the unit economics of the core business are sound. The active customer metric — defined as customers who have purchased within the trailing 52 weeks — grew from approximately 8 million at IPO to a peak of approximately 21 million in fiscal 2022, then moderated to approximately 20 million as the post-COVID normalization of e-commerce reduced tailwind. The slight reduction in active customers has been more than offset by the increase in net sales per active customer, which reflects the deepening of the Chewy relationship through pharmacy adoption, Autoship penetration, and expanded category coverage. Chewy's balance sheet carries manageable debt and has been strengthened by operating cash flow generation. The company has no near-term capital structure concerns, and its cash position provides meaningful strategic optionality for the healthcare platform buildout.